Epigenomics AG
Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet

Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet

Berlin, February 15, 2024 – Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Board and the Supervisory Board, the Charlottenburg District Court has appointed Mr. Jochen Hummel as a member of the Company’s Supervisory Board effective February 5, 2024. Mr. Hummel replaces Dr. Heikki Lanckriet, who stepped down from the Board on January 31, 2024. For the time being, Mr. Hummel’s appointment will end with the Annual General Meeting of Epigenomics AG, which is scheduled to take place on May 29, 2024.

Jochen Hummel has been a partner at WSB Wolf Beckerbauer Hummel & Partner, Steuerberatungsgesellschaft mbB since 2011. As a tax advisor and specialist consultant for international tax law, he is an expert in the field of corporate transactions, international tax law and group structures.

Dr. Helge Lubenow, Chairwoman of the Supervisory Board: “We are very much looking forward to working with Mr. Hummel and his extensive expertise, which will enrich our Board.”

Contact:
Company
Epigenomics AG, Bertha-Benz-Strasse 5, 10557 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com

Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG’s actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.